Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 1 · 12.5%Very low 0 · 0%Low 2 · 25%Moderate 4 · 50%High 0 · 0%

Standard testing plus PET/CT scanning vs standard testing alone

Cancer‐related mortality at maximal · people with unprovoked VTE

Standard testing plus PET/CT scanning showed no clear difference in cancer‐related mortality3 compared with standard testing alone (moderate certainty).

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
OR 0.55 [0.2, 1.52]
2 studies · 1248 participants
Moderate

Standard testing plus PET/CT scanning vs standard testing alone

VTE‐related mortality4 · people with unprovoked VTE

The review found no eligible studies for this question.

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard testing plus PET/CT scanning vs standard testing alone

VTE‐related morbidity5 · people with unprovoked VTE

Standard testing plus PET/CT scanning showed no clear difference in VTE‐related morbidity5 compared with standard testing alone (moderate certainty).

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
OR 1.02 [0.48, 2.17]
1 study · 854 participants
Moderate

Standard testing plus PET/CT scanning vs standard testing alone

Stage at diagnosis (early-stage detection) · people with unprovoked VTE

Standard testing plus PET/CT scanning showed no clear difference in stage of cancer ‐ early compared with standard testing alone (low certainty).

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
OR 1.78 [0.51, 6.17]
1 study · 394 participants
Low

Standard testing plus PET/CT scanning vs standard testing alone

Stage of cancer ‐ advanced · people with unprovoked VTE

Standard testing plus PET/CT scanning showed no clear difference in stage of cancer ‐ advanced compared with standard testing alone (low certainty).

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
OR 1 [0.14, 7.17]
1 study · 394 participants
Low

Standard testing plus PET/CT scanning vs standard testing alone

Time to cancer diagnosis7 · people with unprovoked VTE

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 854 participants
GRADE not reported

Standard testing plus PET/CT scanning vs standard testing alone

Frequency of an underlying cancer diagnosis8 · people with unprovoked VTE

Standard testing plus PET/CT scanning showed no clear difference in frequency of an underlying cancer diagnosis8 compared with standard testing alone (moderate certainty).

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
OR 1.71 [0.91, 3.2]
2 studies · 1248 participants
Moderate

Standard testing plus PET/CT scanning vs standard testing alone

All‐cause mortality1 · people with unprovoked VTE

Standard testing plus PET/CT scanning showed no clear difference in all‐cause mortality1 compared with standard testing alone (moderate certainty).

1 finding from 1 review

Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with… 2021 · Cochrane Headline outcomes only
OR 1.22 [0.49, 3.04]
2 studies · 1248 participants
Moderate